Grupo de Investigación en Genética, Vacunas, Infecciones y Pediatría, Instituto de Investigación Sanitaria de Santiago, Hospital Clinico Universitario and Universidade de Santiago de Compostela, Servizo Galego de Saúde, Galicia, Spain.
Laboratorio de Inmunologìa, Servicio de Análisis Clìnicos, Hospital Clìnico Universitario Santiago de Compostela, Servizo Galego de Saúde, Galicia, Spain.
Front Immunol. 2020 Sep 23;11:560381. doi: 10.3389/fimmu.2020.560381. eCollection 2020.
Emerging evidence indicates a potential role for monocytes in COVID-19 immunopathology. We investigated two soluble markers of monocyte activation, sCD14 and sCD163, in COVID-19 patients, with the aim of characterizing their potential role in monocyte-macrophage disease immunopathology. To the best of our knowledge, this is the first study of its kind.
Fifty-nine SARS-Cov-2 positive hospitalized patients, classified according to ICU or non-ICU admission requirement, were prospectively recruited and analyzed by ELISA for levels of sCD14 and sCD163, along with other laboratory parameters, and compared to a healthy control group.
sCD14 and sCD163 levels were significantly higher among COVID-19 patients, independently of ICU admission requirement, compared to the control group. We found a significant correlation between sCD14 levels and other inflammatory markers, particularly Interleukin-6, in the non-ICU patients group. sCD163 showed a moderate positive correlation with the time lapsed from admission to sampling, independently of severity group. Treatment with corticoids showed an interference with sCD14 levels, whereas hydroxychloroquine and tocilizumab did not.
Monocyte-macrophage activation markers are increased and correlate with other inflammatory markers in SARS-Cov-2 infection, in association to hospital admission. These data suggest a preponderant role for monocyte-macrophage activation in the development of immunopathology of COVID-19 patients.
新出现的证据表明单核细胞在 COVID-19 免疫病理学中可能发挥作用。我们研究了 COVID-19 患者两种单核细胞活化的可溶性标志物，sCD14 和 sCD163，旨在描述它们在单核细胞-巨噬细胞疾病免疫病理学中的潜在作用。据我们所知，这是此类研究中的首例。
前瞻性招募了 59 名 SARS-CoV-2 阳性住院患者，根据入住 ICU 或非 ICU 的要求进行分类，并通过 ELISA 检测 sCD14 和 sCD163 水平以及其他实验室参数，并与健康对照组进行比较。
与对照组相比，COVID-19 患者的 sCD14 和 sCD163 水平无论是否需要入住 ICU，均显著升高。我们发现非 ICU 患者组 sCD14 水平与其他炎症标志物（特别是白细胞介素 6）之间存在显著相关性。sCD163 与从入院到采样的时间间隔呈中度正相关，而与严重程度无关。皮质激素治疗与 sCD14 水平的干扰有关，而羟氯喹和托珠单抗则没有。
在 SARS-CoV-2 感染中，单核细胞-巨噬细胞活化标志物增加，并与其他炎症标志物相关，与住院有关。这些数据表明，在 COVID-19 患者的免疫病理学发展中，单核细胞-巨噬细胞的激活起着主导作用。
